The Rising Threat of Hepatocellular Carcinoma in the Middle East and North Africa Region: Results From Global Burden of Disease Study 2017.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
   Guideline
2. Current and Future Landscape of Hepatocellular Carcinoma Treatment.Oncology research · 2026
   Review
3. Hepatitis C in North Africa: A Comprehensive Review of Epidemiology, Genotypic Diversity, and Hepatocellular Carcinoma.Advances in virology · 2025
   Review
4. Risk of Malignancy in Indeterminate Liver Nodules Among Patients with Cirrhosis: A Retrospective Cohort Study.Journal of gastrointestinal cancer · 2024
   Article
5. Development of a flexible liver phantom for hepatocellular carcinoma treatment planning: a useful tool for training & education.3D printing in medicine · 2024
   Article
6. Recent Advances in Anticancer Activity of Novel Plant Extracts and Compounds from Curcuma longa in Hepatocellular Carcinoma.Journal of gastrointestinal cancer · 2023
   Review
7. Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations.Cancers · 2023
   Review
8. Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery.Frontiers in oncology · 2023
   Article
9. Digital Marketing: A Unique Multidisciplinary Approach towards the Elimination of Viral Hepatitis.Pathogens (Basel, Switzerland) · 2022
   Review
10. Exosomes Derived from microRNA-27a-3p Overexpressing Mesenchymal Stem Cells Inhibit the Progression of Liver Cancer through Suppression of Golgi Membrane Protein 1.Stem cells international · 2022
    Article
11. Variable Proportions of Phylogenetic Clustering and Low Levels of Antiviral Drug Resistance among the Major HBV Sub-Genotypes in the Middle East and North Africa.Pathogens (Basel, Switzerland) · 2021
    Article
12. Drug Discovery in Liver Disease Using Kinome Profiling.International journal of molecular sciences · 2021
    Review
13. Cancer incidence in the Tobruk area, eastern Libya: first results from Tobruk Medical Centre.Epidemiology and health · 2021
    Article
14. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2020
    Article
15. Liver Cancer and Risk Factors in the MENA Region: Epidemiology and Temporal Trends Based on the 2019 Global Burden of Disease Data.Cancer control : journal of the Moffitt Cancer Center
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.